Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

Key facts

Sponsor

Zhejiang University

Principal Investigator

He Huang, MD

First Affiliated Hospital of Zhejiang University

Intervention

CD5 CAR T-cells(biological)

Enrollment

30 target

Eligibility

All sexes

Timeline

2024 – 2027

Study locations (1)

• The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China

Collaborators

Yake Biotechnology Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Precursor T-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07250087
  Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
  H. Lee Moffitt Cancer Center and Research Institute
• RECRUITINGNCT06976736
  A Long Term Follow-up Study of TScan TCR-T Products
  TScan Therapeutics, Inc.
• RECRUITINGPHASE1, PHASE2NCT07070323
  A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06648889
  Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
  Goethe University
• RECRUITINGPHASE1NCT06326463
  CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
  St. Jude Children's Research Hospital
• RECRUITINGPHASE2NCT06220487
  A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
  Nanfang Hospital, Southern Medical University
• RECRUITINGPHASE2NCT07021677
  Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
  Tata Memorial Centre
• ACTIVE NOT RECRUITINGPHASE2NCT04778579
  Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
  Sara V. Latorre

See all trials for Precursor T-cell acute lymphoblastic leukemia →